Presentation is loading. Please wait.

Presentation is loading. Please wait.

Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic.

Published byWesley Burke Modified over 8 years ago

Similar presentations

Presentation on theme: "Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic."— Presentation transcript:

1 Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)? Edward A. Neuwelt, Bronwyn E. Hamilton, Csanad G. Varallyay, William R. Rooney, Robert D. Edelman, Paula M. Jacobs, Suzanne G. Watnick Kidney International Volume 75, Issue 5, Pages 465-474 (March 2009) DOI: 10.1038/ki.2008.496 Copyright © 2009 International Society of Nephrology Terms and Conditions Terms and Conditions

2 Figure 1 Kidney International 2009 75, 465-474DOI: (10.1038/ki.2008.496) Copyright © 2009 International Society of Nephrology Terms and Conditions Terms and Conditions

3 Figure 2 Kidney International 2009 75, 465-474DOI: (10.1038/ki.2008.496) Copyright © 2009 International Society of Nephrology Terms and Conditions Terms and Conditions

4 Figure 3 Kidney International 2009 75, 465-474DOI: (10.1038/ki.2008.496) Copyright © 2009 International Society of Nephrology Terms and Conditions Terms and Conditions

5 Figure 4 Kidney International 2009 75, 465-474DOI: (10.1038/ki.2008.496) Copyright © 2009 International Society of Nephrology Terms and Conditions Terms and Conditions

6 Figure 5 Kidney International 2009 75, 465-474DOI: (10.1038/ki.2008.496) Copyright © 2009 International Society of Nephrology Terms and Conditions Terms and Conditions

7 Figure 6 Kidney International 2009 75, 465-474DOI: (10.1038/ki.2008.496) Copyright © 2009 International Society of Nephrology Terms and Conditions Terms and Conditions

8 Figure 7 Kidney International 2009 75, 465-474DOI: (10.1038/ki.2008.496) Copyright © 2009 International Society of Nephrology Terms and Conditions Terms and Conditions

9 Figure 8 Kidney International 2009 75, 465-474DOI: (10.1038/ki.2008.496) Copyright © 2009 International Society of Nephrology Terms and Conditions Terms and Conditions

10 Figure 9 Kidney International 2009 75, 465-474DOI: (10.1038/ki.2008.496) Copyright © 2009 International Society of Nephrology Terms and Conditions Terms and Conditions

11 Figure 10 Kidney International 2009 75, 465-474DOI: (10.1038/ki.2008.496) Copyright © 2009 International Society of Nephrology Terms and Conditions Terms and Conditions

12 Figure 11 Kidney International 2009 75, 465-474DOI: (10.1038/ki.2008.496) Copyright © 2009 International Society of Nephrology Terms and Conditions Terms and Conditions

Download ppt "Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic."

Similar presentations

Telomerase deficiency delays renal recovery in mice after ischemia–reperfusion injury by impairing autophagy Huifang Cheng, Xiaofeng Fan, William E. Lawson,

Telomerase deficiency delays renal recovery in mice after ischemia–reperfusion injury by impairing autophagy Huifang Cheng, Xiaofeng Fan, William E. Lawson,
Renal involvement in hepatitis C infection: Cryoglobulinemic glomerulonephritis Giuseppe D’Amico Kidney International Volume 54, Issue 2, Pages 650-671.

Renal involvement in hepatitis C infection: Cryoglobulinemic glomerulonephritis Giuseppe D’Amico Kidney International Volume 54, Issue 2, Pages
A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and.

A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and.
Epidemiology of end-stage renal disease: International comparisons of renal replacement therapy Francesco Paolo Schena Kidney International Volume 57,

Epidemiology of end-stage renal disease: International comparisons of renal replacement therapy Francesco Paolo Schena Kidney International Volume 57,
Mast cell activation and degranulation promotes renal fibrosis in experimental unilateral ureteric obstruction Shaun A. Summers, Poh-yi Gan, Lakshi Dewage,

Mast cell activation and degranulation promotes renal fibrosis in experimental unilateral ureteric obstruction Shaun A. Summers, Poh-yi Gan, Lakshi Dewage,
Renal Stress Testing in the Assessment of Kidney Disease Lakhmir S. Chawla, Claudio Ronco Kidney International Reports Volume 1, Issue 1, Pages 57-63 (May.

Renal Stress Testing in the Assessment of Kidney Disease Lakhmir S. Chawla, Claudio Ronco Kidney International Reports Volume 1, Issue 1, Pages (May.
An alcoholic patient with recurrent renal failure and proteinuria T. Kumagai, Y. Hori, G. Seki, Toshiro Fujita Kidney International Volume 70, Issue 8,

An alcoholic patient with recurrent renal failure and proteinuria T. Kumagai, Y. Hori, G. Seki, Toshiro Fujita Kidney International Volume 70, Issue 8,
Chapter 1: Definition and classification of CKD Kidney International Supplements Volume 3, Issue 1, Pages 19-62 (January 2013) DOI: 10.1038/kisup.2012.64.

Chapter 1: Definition and classification of CKD Kidney International Supplements Volume 3, Issue 1, Pages (January 2013) DOI: /kisup
Evaluation and treatment of coronary artery disease in patients with end-stage renal disease Peter A. McCullough Kidney International Volume 67, Pages.

Evaluation and treatment of coronary artery disease in patients with end-stage renal disease Peter A. McCullough Kidney International Volume 67, Pages.
Volume 75, Issue 5, Pages (March 2009)

Volume 75, Issue 5, Pages (March 2009)
Use of hemodialysis and hemoperfusion in poisoned patients

Use of hemodialysis and hemoperfusion in poisoned patients
Propofol-related green urine

Propofol-related green urine
Recalcitrant pain in a patient with ADPKD

Recalcitrant pain in a patient with ADPKD
Anemia management in chronic kidney disease

Anemia management in chronic kidney disease
Mitchell H. Rosner, W. Kline Bolton  Kidney International 

Mitchell H. Rosner, W. Kline Bolton  Kidney International 
Volume 83, Issue 3, Pages (March 2013)

Volume 83, Issue 3, Pages (March 2013)
Parapelvic cysts leading to a diagnosis of Fabry disease

Parapelvic cysts leading to a diagnosis of Fabry disease
ESA and iron therapy in chronic kidney disease: a balance between patient safety and hemoglobin target  Szu-Chun Hung, Der-Cherng Tarng  Kidney International 

ESA and iron therapy in chronic kidney disease: a balance between patient safety and hemoglobin target  Szu-Chun Hung, Der-Cherng Tarng  Kidney International 
Reassessment of the care of the patient with chronic kidney disease

Reassessment of the care of the patient with chronic kidney disease
John P. Middleton, Patrick H. Pun  Kidney International 

John P. Middleton, Patrick H. Pun  Kidney International 

Similar presentations

Ads by Google